|
[1] TREPO C,CHAN HLY,LOK A. Hepatitis B virus infection[J].Lancet,2014,384(9959):2053-2063.
|
|
[2] MOLINARO A,WAHLSTROM A,MARSCHALL HU. Role of bile acids in metabolic control[J]. Trends Endocrinol Metab,2018,29(1):31-41.
|
|
[3] DAWSON PA,KARPEN SJ. Intestinal transport and metabolism of bile acids[J]. J Lipid Res,2015,56(6):1085-1099.
|
|
[4] DI CIAULA A,GARRUTI G,LUNARDI BACCETTO R,et al.Bile acid physiology[J]. Ann Hepatol,2017,16(Suppl 1):s4-s14.
|
|
[5] ANIC'M,STANIMIROV B,PAVLOVIC'N,et al. Pharmacological applications of bile acids and their derivatives in the treatment of metabolic syndrome[J]. Front Pharmacol,2018,9:1382.
|
|
[6] DORING B,LUTTEKE T,GEYER J,et al. The SLC10 carrier family:Transport functions and molecular structure[J]. Curr Top Membr,2012,70:105-168.
|
|
[7] SLIJEPCEVIC D,KAUFMAN C,WICHERS CG,et al. Impaired uptake of conjugated bile acids and hepatitis b virus pres1-binding in na(+)-taurocholate cotransporting polypeptide knockout mice[J]. Hepatology,2015,62(1):207-219.
|
|
[8] YAN H,ZHONG G,XU G,et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus[J]. Elife,2012,1:e00049.
|
|
[9] KONIG A,DORING B,MOHR C,et al. Kinetics of the bile acid transporter and hepatitis B virus receptor Na+/taurocholate cotransporting polypeptide(NTCP)in hepatocytes[J]. J Hepatol,2014,61(4):867-875.
|
|
[10] OEHLER N,VOLZ T,BHADRA OD,et al. Binding of hepatitis B virus to its cellular receptor alters the expression profile of genes of bile acid metabolism[J]. Hepatology,2014,60(5):1483-1493.
|
|
[11] MATAKI C,MAGNIER BC,HOUTEN SM,et al. Compromised intestinal lipid absorption in mice with a liver-specific deficiency of liver receptor homolog 1[J]. Mol Cell Biol,2007,27(23):8330-8339.
|
|
[12] LEE YK,SCHMIDT DR,CUMMINS CL,et al. Liver receptor homolog-1 regulates bile acid homeostasis but is not essential for feedback regulation of bile acid synthesis[J]. Mol Endocrinol,2008,22(6):1345-1356.
|
|
[13] SUHAIL M,ABDEL-HAFIZ H,ALI A,et al. Potential mechanisms of hepatitis B virus induced liver injury[J]. World J Gastroenterol,2014,20(35):12462-12472.
|
|
[14] JUNG MK,SHIN EC. Regulatory T cells in hepatitis B and C virus infections[J]. Immune Netw,2016,16(6):330-336.
|
|
[15] BERTOLETTI A,FERRARI C. Adaptive immunity in HBV infection[J]. J Hepatol,2016,64(1 Suppl):s71-s83.
|
|
[16] WU S,WANG W,GAO Y. Natural killer cells in hepatitis B virus infection[J]. Braz J Infect Dis,2015,19(4):417-425.
|
|
[17] OH IS,PARK SH. Immune-mediated liver injury in hepatitis B virus infection[J]. Immune Network,2015,15(4):191-198.
|
|
[18] ALEGRE F,PELEGRIN P,FELDSTEIN AE. Inflammasomes in liver fibrosis[J]. Semin Liver Dis,2017,37(2):119-127.
|
|
[19] KIM HY,CHO HK,CHOI YH,et al. Bile acids increase hepatitis B virus gene expression and inhibit interferon-αactivity:Bile acid metabolism and HBV gene expression[J]. FEBS J,2010,277(13):2791-2802.
|
|
[20] YAN H,PENG B,LIU Y,et al. Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide[J]. J Virol,2014,88(6):3273-3284.
|
|
[21] HOU Y,FAN W,YANG W,et al. Farnesoid X receptor:An important factor in blood glucose regulation[J]. Clin Chim Acta,2019,495:29-34.
|
|
[22] MOUZANNAR K,FUSIL F,LACOMBE B,et al. Farnesoid X receptor-αis a proviral host factor for hepatitis B virus that is inhibited by ligands in vitro and in vivo[J]. FASEB J,2019,33(2):2472-2483.
|
|
[23] REESE VC,OROPEZA CE,MCLACHLAN A. Independent activation of hepatitis B virus biosynthesis by retinoids,peroxisome proliferators,and bile acids[J]. J Virol,2013,87(2):991-997.
|
|
[24] RADREAU P,PORCHEROT M,RAMIERE C,et al. Reciprocal regulation of farnesoid X receptorαactivity and hepatitis B virus replication in differentiated HepaRG cells and primary human hepatocytes[J]. FASEB J,2016,30(9):3146-3154.
|
|
[25] HU M. The mechanisms of bile acid receptor FXR in HBV infection[D]. Kaifeng:Henan University,2018.(in Chinese)胡敏．胆汁酸受体FXR在HBV感染中的作用机制研究[D]．开封:河南大学，2018.
|
|
[26] RAMIERE C,SCHOLTES C,DIAZ O,et al. Transactivation of the hepatitis B virus core promoter by the nuclear receptor FXRalpha[J]. J Virol,2008,82(21):10832-10840.
|
|
[27] ZHAO K,LIU S,CHEN Y,et al. Upregulation of HBV transcription by sodium taurocholate cotransporting polypeptide at the postentry step is inhibited by the entry inhibitor Myrcludex B[J]. Emerg Microbes Infect,2018,7(1):186.
|
|
[28] DAI J,WANG H,SHI Y,et al. Impact of bile acids on the growth of human cholangiocarcinoma via FXR[J]. J Hematol Oncol,2011,4:41.
|
|
[29] MAKISHIMA M,OKAMOTO AY,REPA JJ,et al. Identification of a nuclear receptor for bile acids[J]. Science,1999,284(5418):1362-1365.
|
|
[30] LI Y,JADHAV K,ZHANG Y. Bile acid receptors in non-alcoholic fatty liver disease[J]. Biochem Pharmacol,2013,86(11):1517-1524.
|
|
[31] LEW JL,ZHAO A,YU J,et al. The farnesoid X receptor controls gene expression in a ligand-and promoter-selective fashion[J]. J Biol Chem,2004,279(10):8856-8861.
|
|
[32] YU SJ,YE WH,ZOU ZS,et al. Determination of total bile acid in HBV-related liver diseases and its clinical significance[J].J Prac Hepatol,2010,13(2):136-137.(in Chinese)于双杰，叶文华，邹正升，等．HBV相关肝病总胆汁酸测定及其临床意义[J]．实用肝脏病杂志，2010,13(2):136-137.
|
|
[33] WANG H,SHANG X,WAN X,et al. Increased hepatocellular carcinoma risk in chronic hepatitis B patients with persistently elevated serum total bile acid:A retrospective cohort study[J]. Sci Rep,2016,6:38180.
|
|
[34] YAN MX,WANG WQ,LIU Q,et al. Clinical value of detecting serum preAIB and total bile acid of patients with chronic liver diseases[J]. Shandong Med J,2000,40(13):3-4.(in Chinese)闫明先，王文奇，刘倩，等．血清前白蛋白和总胆汁酸联合检测在慢性肝病中的临床价值[J]．山东医药，2000,40(13):3-4.
|
|
[35] MASUBUCHI N,SUGIHARA M,SUGITA T,et al. Oxidative stress markers,secondary bile acids and sulfated bile acids classify the clinical liver injury type:Promising diagnostic biomarkers for cholestasis[J]. Chem Biol Interact,2016,255:83-91.
|
|
[36] SUN GZ,LI Q,MIN FY. The study of clinic value of prealbumin,cholinesterase and total bile acid in diagnosing the histologic staging in patients with chronic hepatitis B[J]. Chin J Lab Med,2004,27(8):33-34.(in Chinese)孙桂珍，李琴，闵福援．前白蛋白、胆碱酯酶与胆汁酸对慢性乙型病毒性肝炎病理分级临床价值的研究[J]．中华检验医学杂志，2004,27(8):33-34.
|
|
[37] OU XJ,WANG XM,JIA JD,et al. Evaluation of correlation between hepatic pathohistology of biopsies and liver function or serum HBV DNA in patients with chronic hepatitis B[J]. J Capital Univ Med Sci,2006,27(4):435-437.(in Chinese)欧晓娟，王晓明，贾继东，等．慢性乙型肝炎肝穿病理与血清HBV DNA及肝功能的关系[J]．首都医科大学学报，2006,27(4):435-437.
|
|
[38] WANG X,XIE G,ZHAO A,et al. Serum bile acids are associated with pathological progression of hepatitis B-induced cirrhosis[J]. J Proteome Res,2016,15(4):1126-1134.
|
|
[39] ZHANG LL,FAN YJ,TAN B,et al. Recognition of the clinical application and biological mechanism of ursodeoxycholic acid in liver diseases[J]. Chin J Clin Pharmacol Ther,2017,22(2):233-240.(in Chinese)张林林，樊玉娟，谭波，等．熊脱氧胆酸在慢性肝病中应用及机制的再认识[J]．中国临床药理学与治疗学，2017,22(2):233-240.
|
|
[40] WANG XY,SHEN SR,LI N,et al. Effect of Ursodeoxycholi acid on liver cirrhosis with hepatitis B[J]. J Cent South Univ(Med Sci),2010,35(2):171-175.(in Chinese)王晓艳，沈守荣，李楠，等．熊去氧胆酸治疗乙型肝炎肝硬化的临床疗效[J]．中南大学学报(医学版)，2010,35(2):171-175.
|
|
[41] CHEN W,LIU J,GLUUD C. Bile acids for viral hepatitis[J].Cochrane Database Syst Rev,2007,4:CD003181.
|
|
[42] BARONE M,MAIORANO E,LADISA R,et al. Influence of ursodeoxycholate-enriched diet on liver tumor growth in HBV transgenic mice[J]. Hepatology,2003,37(4):880-86.
|
DownLoad: